These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 10651342)

  • 21. Fluconazole improves survival in septic shock: a randomized double-blind prospective study.
    Jacobs S; Price Evans DA; Tariq M; Al Omar NF
    Crit Care Med; 2003 Jul; 31(7):1938-46. PubMed ID: 12847386
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanism of traumatic shock.
    Hardaway RM
    Surg Gynecol Obstet; 1980 Jul; 151(1):65-9. PubMed ID: 6446168
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Current concepts in the pathogenesis and treatment of abortion and septic shock. II. The physiopathological bases and outlook in the management of septic shock].
    Figueroa Damian R; Arredondo García JL
    Ginecol Obstet Mex; 1993 Dec; 61():337-43. PubMed ID: 8119603
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Diagnosis of the disseminated intravascular coagulation syndrome in septic shock].
    Makatsariia AD; Dobrovol'skiĭ VI
    Sov Med; 1981; (6):34-9. PubMed ID: 7280793
    [No Abstract]   [Full Text] [Related]  

  • 25. Experimental research on endotoxic shock in urology.
    Blaja C; Popescu A
    Eur Urol; 1975; 1(2):101-2. PubMed ID: 786647
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cellular and metabolic effects of shock.
    Hardaway RM
    J Am Vet Med Assoc; 1979 Jul; 175(1):81-6. PubMed ID: 387685
    [No Abstract]   [Full Text] [Related]  

  • 27. Treatment of fulminant meningococcemia with recombinant tissue plasminogen activator.
    Zenz W; Muntean W; Zobel G; Grubbauer HM; Gallistl S
    Thromb Haemost; 1995 Aug; 74(2):802-3. PubMed ID: 8585030
    [No Abstract]   [Full Text] [Related]  

  • 28. Experimental models of sepsis and their clinical relevance.
    Poli-de-Figueiredo LF; Garrido AG; Nakagawa N; Sannomiya P
    Shock; 2008 Oct; 30 Suppl 1():53-9. PubMed ID: 18704008
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [[Antithrombin III concentrates in the treatmetn of sepsis and septic shock: indictions, limits and future prospects] ].
    Baudo F; de Cataldo F
    Minerva Anestesiol; 2000 Nov; 66(11 Suppl 1):3-23. PubMed ID: 11213542
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Infectious-toxic shock and disseminated intravascular coagulation in a pregnant woman with influenza].
    Anisimova IuN; Trushnikova GV
    Arkh Patol; 1994; 56(3):79-82. PubMed ID: 8092950
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of intravascular coagulation in feline endotoxin shock.
    Lucas WE; Kitzmiller JL
    Surg Gynecol Obstet; 1972 Jan; 134(1):73-7. PubMed ID: 5007178
    [No Abstract]   [Full Text] [Related]  

  • 32. Activation of the fibrinolytic system and utilization of the coagulation inhibitors in sepsis: comparison with severe sepsis and septic shock.
    Mavrommatis AC; Theodoridis T; Economou M; Kotanidou A; El Ali M; Christopoulou-Kokkinou V; Zakynthinos SG
    Intensive Care Med; 2001 Dec; 27(12):1853-9. PubMed ID: 11797019
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacological utility of melatonin in the treatment of septic shock: experimental and clinical evidence.
    Escames G; Acuña-Castroviejo D; López LC; Tan DX; Maldonado MD; Sánchez-Hidalgo M; León J; Reiter RJ
    J Pharm Pharmacol; 2006 Sep; 58(9):1153-65. PubMed ID: 16945173
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Experimental study on the prognostic criteria of endotoxin shock complicated by disseminated intravascular coagulation].
    He SL
    Zhonghua Yi Xue Za Zhi; 1987 Oct; 67(10):552-5. PubMed ID: 3127007
    [No Abstract]   [Full Text] [Related]  

  • 35. [Ultrastructural manifestations of pulmonary thrombohemorrhagic syndrome in endotoxic shock].
    Bardakhch'ian EA; Kharlanova NG
    Biull Eksp Biol Med; 1990 Jan; 109(1):82-4. PubMed ID: 2334807
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Antithrombin: prospects in clinical practice. Sespsi: anticoagulant or anti-inflammatory agents?].
    Imberti D
    Minerva Anestesiol; 2003 May; 69(5):371-5. PubMed ID: 12768169
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between effect of polymyxin B-immobilized fiber and high-mobility group box-1 protein in septic shock patients.
    Sakamoto Y; Mashiko K; Matsumoto H; Hara Y; Kutsukata N; Yamamoto Y
    ASAIO J; 2007; 53(3):324-8. PubMed ID: 17515723
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Shock: a review. I: Pathophysiology].
    Schrauwen E
    Tijdschr Diergeneeskd; 1984 Dec; 109(23):957-67. PubMed ID: 6151264
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Role of coagulopathies in the pathogenesis of septic shock].
    Makatsariia AD; Bokarev IN; Mel'nikov AP
    Akush Ginekol (Mosk); 1978 May; (5):4-8. PubMed ID: 352173
    [No Abstract]   [Full Text] [Related]  

  • 40. The current management of septic shock.
    Russel JA
    Minerva Med; 2008 Oct; 99(5):431-58. PubMed ID: 18971911
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.